Loading clinical trials...

Treating Verbal Memory Deficits Following Chemotherapy for Breast Cancer | Clinical Trials | Clareo Health

COMPLETEDNA

Treating Verbal Memory Deficits Following Chemotherapy for Breast Cancer

NCT03017560•Northwestern University

Summary

The primary purpose of this study is to test the effects of a targeted, computerized cognitive training program on verbal memory in older women who have undergone chemotherapy treatment for early-stage breast cancer. As measured by neuropsychological assessment, this treatment will result in improved verbal memory. Secondarily, processing speed and naming abilities are expected to improve. Enhanced self-perception of cognitive ability is also expected.

Eligibility

Age

65 - 90 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Women ages 65-90
•Chemotherapy treatment for early-stage (I, IIa, IIb, IIIa) breast cancer
•Post-menopausal
•High school education or greater
•Geographically available for followup assessment
•Native English speaker
•Normal or corrected to near-normal hearing and vision

Exclusion Criteria

•Psychiatric history including past or current psychotic spectrum disorders (schizophrenia, bipolar disorder, major depressive disorder, dementia, schizoaffective disorder)
•Brain injury (e.g., stroke, heart attack, aneurysm, tumor, concussion, head trauma)
•Brain disease
•History of brain irradiation or surgery
•Current or past disease/disorder of the central nervous system or medical condition affecting cognitive functioning (e.g., chronic migraine, epilepsy or history of seizures, encephalitis, meningitis, multiple sclerosis, thyroid condition, Parkinson's, Alzheimer's, Huntington's disease)
•Active diagnosis of autoimmune or inflammatory disorder (e.g., systemic lupus erythematosus, rheumatoid arthritis, vasculitis, insulin-dependent diabetes, Crohn's disease, uncontrolled allergic reaction or asthma)
•History of other cancer, except for basal cell carcinoma
•Development of a second primary malignancy during the study
•Drug or alcohol abuse (i.e., more than 7 drinks per week)
•Chronic use of oral steroid medication
+3 more criteria

Key Dates

Start Date

December 1, 2015

Primary Completion Date

May 1, 2017

Completion Date

May 1, 2017

Last Updated

November 7, 2023

Enrollment

ACTUAL participants

Conditions

Breast Cancer TreatmentCognitive Deficits

Interventions

Computerized cognitive treatment

BEHAVIORAL

Neuromodulation and Attention Deficits in MDD

NCT07111169

Major Depression DisorderCognitive Deficits+1 more

View study

NOT_YET_RECRUITINGNA

Early Intervention

NCT05326165

Breast CancerBreast Cancer Treatment Related Lymphedema

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 7, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treating Verbal Memory Deficits Following Chemotherapy for Breast Cancer

Inclusion Criteria

Exclusion Criteria

Neuromodulation and Attention Deficits in MDD

Early Intervention

Memantine Hydrochloride for Treatment of Cognitive Dysfunction Due to Traumatic Brain Injury

Involving Family to Improve Communication in Breast Cancer Care

Can Cognitive Training Decrease Reactive Aggression?

Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia